Share This Page
Drug Price Trends for TREMFYA
✉ Email this page to a colleague
Average Pharmacy Cost for TREMFYA
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TREMFYA 100 MG/ML ONE-PRESS | 57894-0640-11 | 14051.07900 | ML | 2025-11-19 |
| TREMFYA 100 MG/ML SYRINGE | 57894-0640-01 | 14088.01333 | ML | 2025-11-19 |
| TREMFYA 100 MG/ML ONE-PRESS | 57894-0640-11 | 14031.25118 | ML | 2025-10-22 |
| TREMFYA 100 MG/ML SYRINGE | 57894-0640-01 | 14073.73000 | ML | 2025-10-22 |
| TREMFYA 100 MG/ML SYRINGE | 57894-0640-01 | 14073.73000 | ML | 2025-09-17 |
| TREMFYA 100 MG/ML ONE-PRESS | 57894-0640-11 | 14031.25118 | ML | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for TREMFYA
Introduction
TREMFYA (guselkumab) is a monoclonal antibody developed by Janssen Pharmaceuticals for the treatment of moderate to severe plaque psoriasis and other immune-mediated conditions. Since its FDA approval in July 2017, TREMFYA has positioned itself as a leading biologic therapy within the psoriasis treatment landscape. Given the evolving competitive dynamics, patent protections, and changes in healthcare policies, understanding the current market outlook and future pricing projections is crucial for stakeholders. This analysis synthesizes recent market developments, competitive factors, regulatory influences, and pricing trends to inform strategic decision-making.
Market Landscape for TREMFYA
Global Market Size and Growth
The global psoriasis market was valued at approximately USD 12 billion in 2021, with biologics driving substantial growth due to their efficacy and favorable safety profiles compared to traditional systemic therapies[^1]. TREMFYA, as a relatively newer entry, commands a significant share within this segment owing to its targeted mechanism and favorable dosing schedule—every 8 weeks after initial doses—which enhances patient adherence[^2].
In 2022, the biologics segment accounted for over 70% of the total psoriasis market, with a compound annual growth rate (CAGR) of around 7%[^3]. The increasing prevalence of psoriasis—estimated at approximately 125 million globally—bolsters the demand for effective therapies like TREMFYA.
Competitive Landscape
TREMFYA’s primary competitors include other IL-23 inhibitors (e.g., AbbVie's Skyrizi [risankizumab], Novartis’ Tremfya [guselkumab]) and IL-17 inhibitors (e.g., Cosentyx, Taltz). While IL-23 inhibitors have gained favor for their sustained efficacy and safety, the competitive landscape is intensifying with biosimilars on the horizon and newer agents entering development pipelines[^4].
Regulatory and Reimbursement Environment
The expansion of indications—such as psoriatic arthritis and Crohn’s disease—enhances the market potential. However, reimbursement policies and value-based pricing negotiations increasingly influence availability and adoption rates, potentially impacting pricing strategies.
Current Pricing Dynamics
Pricing Benchmarks
In the United States, the list price of TREMFYA per injection (100 mg) ranges approximately between USD 8,000 to USD 9,000[^5]. The recommended dosing regimen involves an initial dose at weeks 0 and 4, followed by maintenance doses every 8 weeks, resulting in annual treatment costs of roughly USD 48,000 to USD 54,000 per patient.
Market Penetration and Pricing Flexibility
Janssen maintains premium pricing justified by clinical efficacy and dosing convenience. However, rebates, discounts, and patient assistance programs play a significant role in negotiated net prices, which often fall below list prices.
Impact of Biosimilars
While biosimilar IL-23 inhibitors are not yet widely available for guselkumab, imminent patent expirations in 2028 could open opportunities for biosimilar entrants, exerting downward pressure on TREMFYA’s pricing.
Future Price Projections
Key Drivers Influencing Future Pricing
-
Patent Expiry and Biosimilar Competition: The primary patent for guselkumab is expected to expire around 2028 in the U.S., paving the way for biosimilar development that could lead to significant price reductions[^6].
-
Market Penetration and Adoption Rates: As physician familiarity increases and new indications expand, TREMFYA is expected to solidify its market share, supporting stable or slightly declining prices initially, with potential decreases post-biosimilar entry.
-
Negotiation and Reimbursement Policies: Governments and payers emphasizing cost containment will likely negotiate steeper discounts, which could reduce net prices by 20-40% over the next 5 years.
-
Regulatory and Clinical Developments: Broader approval for additional indications might sustain or elevate pricing if the therapy demonstrates superior efficacy or safety.
Projected Price Trends (2023-2030)
-
Short-term (2023-2025): Expect minimal change in list prices, with moderate discounts and rebates, maintaining annual treatment costs within USD 45,000 to USD 55,000.
-
Mid-term (2026-2028): Anticipate increased competitive pressure, especially around patent expiry, leading to a 15-25% reduction in net prices, with list prices possibly decreasing by 10-15%.
-
Long-term (2028 onward): Introduction of biosimilars could trigger a 30-50% reduction in net prices, potentially decreasing list prices by 20-30%, aligning with discounts observed in other biologic biosimilars[^7].
Implications and Strategic Considerations
Stakeholders should prepare for a dynamic pricing environment. Innovator companies must explore value-based pricing models, patient assistance programs, and differentiation strategies. Payers and health systems should consider formulary positioning that balances clinical benefits with cost-effectiveness, especially as biosimilar options emerge.
Conclusion
TREMFYA's market remains robust, driven by its clinical profile and market penetration. However, impending patent expiration and biosimilar developments portend significant pricing adjustments. Continuous monitoring of regulatory updates, biosimilar entry timelines, and healthcare policy shifts is essential to optimize market positioning and pricing strategies.
Key Takeaways
- The global psoriasis biologics market is expanding at ~7% CAGR, with TREMFYA holding a significant share.
- Current list prices stand around USD 8,000–USD 9,000 per injection, translating to annual costs of approximately USD 48,000–USD 54,000.
- Patent expiration around 2028 will likely trigger biosimilar competition, leading to substantial reductions in net prices.
- Payers' increased emphasis on cost-effectiveness may necessitate more aggressive discounting and value-based agreements.
- Strategic planning should encompass timing for biosimilar entry, expansion into new indications, and evolving reimbursement landscapes.
FAQs
1. When will TREMFYA face biosimilar competition?
Biosimilars for guselkumab are expected to enter the market post-2028, coinciding with patent expiration in key jurisdictions like the U.S.
2. How might biosimilar entry affect TREMFYA’s prices?
Biosimilar competition could reduce net prices by 30-50%, with list prices potentially decreasing by 20-30%, mirroring trends seen in other biologics.
3. What factors influence TREMFYA's pricing strategy?
Clinical efficacy, dosing convenience, market share, regulatory approvals, biosimilar development, and payer negotiations are primary drivers.
4. Will expanding indications stabilize or lower TREMFYA’s prices?
Broader approvals could extend the product's lifecycle and justify pricing stability or increases, but cost-containment pressures may still lead to discounts.
5. How do regional differences impact TREMFYA’s pricing?
Pricing varies globally, influenced by healthcare policies, reimbursement frameworks, and competitive landscape, with emerging markets often experiencing lower prices.
References
[1] Global Psoriasis Market Report, Market Research Future, 2022.
[2] Janssen Pharmaceuticals, TREMFYA Prescribing Information, 2022.
[3] IQVIA, Biologic Market Insights, 2022.
[4] EvaluatePharma, Biologics Development Pipeline, 2022.
[5] GoodRx, TREMFYA Pricing Data, 2023.
[6] U.S. Patent and Trademark Office, Patent Expiry Calendar, 2023.
[7] IMS Health, Biologics Biosimilar Pricing Trends, 2021.
More… ↓
